Abstract

BackgroundMalignant peripheral nerve sheath tumors (MPNSTs) are a rare subtype of soft-tissue sarcoma, derived from a peripheral branch or the sheath of the sciatic nerve, brachial plexus, or sacral plexus. The clinical outcomes for MPNST patients with unresectable or metastatic tumors are dismal, and novel therapeutic strategies are required. Although patient-derived cancer cell lines are vital for basic research and preclinical studies, few MPNST cell lines are available from public cell banks. Therefore, the aim of this study was to establish cancer cell lines derived from MPNST patients.MethodsWe used tumor tissues from five patients with MPNSTs, including one derived from a rare bone tissue MPNST. The tumor tissues were obtained at the time of surgery and were immediately processed to establish cell lines. A patient-derived xenograft was also established when a sufficient amount of tumor tissue was available. The characterization of established cells was performed with respect to cell proliferation, spheroid formation, and invasion. The mutation status of actionable genes was monitored by NCC Oncopanel, by which the mutation of 114 genes was assessed by next-generation sequencing. The response to anti-cancer agents, including anti-cancer drugs approved for the treatment of other malignancies was investigated in the established cell lines.ResultsWe established five cell lines (NCC-MPNST1-C1, NCC-MPNST2-C1, NCC-MPNST3-C1, NCC-MPNST4-C1, and NCC-MPNST5-C1) from the original tumors, and also established patient-derived xenografts (PDXs) from which one cell line (NCC-MPNST3-X2-C1) was produced. The established MPNST cell lines proliferated continuously and formed spheroids while exhibiting distinct invasion abilities. The cell lines had typical mutations in the actionable genes, and the mutation profiles differed among the cell lines. The responsiveness to examined anti-cancer agents differed among cell lines; while the presence of an actionable gene mutation did not correspond with the response to the anticipated anti-cancer agents.ConclusionThe established cell lines exhibit various characteristics, including proliferation and invasion potential. In addition, they had different mutation profiles and response to the anti-cancer agents. These observations suggest that the established cell lines will be useful for future research on MPNSTs.

Highlights

  • Malignant peripheral nerve sheath tumors (MPNSTs) are a rare subtype of soft-tissue sarcoma, derived from a peripheral branch or the sheath of the sciatic nerve, brachial plexus, or sacral plexus

  • The emergence of MPNSTs is often associated with neurofibromatosis type 1 (NF1), which is an autosomal dominant disorder characterized by plexiform neurofibroma [2, 3]

  • Establishment of patient‐derived xenograft (PDX) models of MPNST MPNST tissues were obtained at the time of surgery and were subcutaneously grafted into the bilateral hind flanks of 6–12-week-old female mice with a severe immunodeficient phenotype (NOD Cg-Prkdcscid Il2rgtm1Sug/Jic, known as NOD/Shi-scid IL-2Rγnull or NOG; Central Institute for Experimental Animals, Kanagawa, Japan) using a 13-gauge transplant needle

Read more

Summary

Introduction

Malignant peripheral nerve sheath tumors (MPNSTs) are a rare subtype of soft-tissue sarcoma, derived from a peripheral branch or the sheath of the sciatic nerve, brachial plexus, or sacral plexus. The clinical outcomes for MPNST patients with unresectable or metastatic tumors are dismal, and novel therapeutic strategies are required. The aim of this study was to establish cancer cell lines derived from MPNST patients. Malignant peripheral nerve sheath tumor (MPNST) is a rare subtype of soft-tissue sarcomas representing approximately 10% of all soft-tissue sarcomas [1]. MPNSTs originate from a peripheral nerve branch or the sheath of the sciatic nerve, brachial plexus, or sacral plexus. The clinical outcome for MPNST patients with unresectable or metastatic tumors is dismal [23, 24], and the 5-year survival rate remains approximately 20–50%.

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call